News
NBY
0.7198
+1.52%
0.0108
Weekly Report: what happened at NBY last week (1111-1115)?
Weekly Report · 3d ago
ISS supports NovaBay proposals to sell Avenova business
TipRanks · 6d ago
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand
Barchart · 6d ago
NovaBay Pharmaceuticals Reports Q3 2024 Financials Amid Strategic Changes
TipRanks · 11/15 04:22
NovaBay Is Maintained at Buy by Ascendiant Capital
Dow Jones · 11/11 17:53
Ascendiant Capital Maintains Buy on NovaBay Pharmaceuticals, Adjusts Price Target To $0.85 (1-35 Reverse Stock Split)
Benzinga · 11/11 17:44
Weekly Report: what happened at NBY last week (1104-1108)?
Weekly Report · 11/11 12:28
Based on the provided financial report article, the title of the article is likely: "10-Q: Nuvo Beauty, Inc. (NBY) Q3 2024 Earnings Report" This title is inferred based on the format of the article, which appears to be a quarterly earnings report filed with the Securities and Exchange Commission (SEC) in the form of a 10-Q filing. The article includes financial statements, notes, and other information related to Nuvo Beauty, Inc.'s (NBY) Q3 2024 earnings.
Press release · 11/08 07:46
NovaBay GAAP EPS of -$0.60 misses by $0.30, revenue of $2.44M misses by $0.19M
Seeking Alpha · 11/08 05:01
NovaBay accepts higher PRN offer, says Refresh deal no longer superior
Seeking Alpha · 11/06 21:49
NovaBay accepts revised transaction proposal from PRN
TipRanks · 11/06 21:34
*NovaBay Pharmaceuticals: Accepted Revised Offer From PRN Physician Recommended Nutriceuticals
Dow Jones · 11/06 21:20
*NovaBay: Entered Into an Amendment to the Asset Purchase Agreement to Increase Purchase Price>NBY
Dow Jones · 11/06 21:20
*NovaBay: Increased the Base Purchase Price for the Company's Eyecare Business From $9.5M to $11.5M >NBY
Dow Jones · 11/06 21:20
Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 11/05 13:15
Weekly Report: what happened at NBY last week (1028-1101)?
Weekly Report · 11/04 12:22
Biotech Alert: Searches spiking for these stocks today
TipRanks · 11/01 15:20
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/31 15:05
NovaBay Pharmaceuticals receives unsolicited offer from Refresh Acquisitions
Seeking Alpha · 10/29 13:00
NovaBay board determines Refresh Acquisitions offer is superior to PRN pact
TipRanks · 10/29 12:15
More
Webull provides a variety of real-time NBY stock news. You can receive the latest news about Novabay Pharma through multiple platforms. This information may help you make smarter investment decisions.
About NBY
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. It offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. It also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.